Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Synlogic, Inc.
  6. Summary
    SYBX   US87166L1008

SYNLOGIC, INC.

(SYBX)
  Report
Delayed Quote. Delayed Nasdaq - 09/20 04:00:00 pm
3.71 USD   +12.77%
01:40pTop Midday Gainers
MT
01:36pSYNLOGIC : Piper Sandler Adjusts Synlogic PT to $9 From $7, Maintains Overweight Rating
MT
09:52aSYNLOGIC : PKU Clinical Program Update
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/14/2021 09/15/2021 09/16/2021 09/17/2021 09/20/2021 Date
3.02(c) 3.17(c) 3.19(c) 3.29(c) 3.71 Last
108 628 234 544 115 324 272 913 9 321 342 Volume
+1.00% +4.97% +0.63% +3.13% +12.77% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 0,47 M - -
Net income 2021 -61,4 M - -
Net cash position 2021 84,4 M - -
P/E ratio 2021 -2,57x
Yield 2021 -
Sales 2022 0,36 M - -
Net income 2022 -67,7 M - -
Net cash position 2022 18,0 M - -
P/E ratio 2022 -2,73x
Yield 2022 -
Capitalization 172 M 172 M -
EV / Sales 2021 187x
EV / Sales 2022 424x
Nbr of Employees 72
Free-Float 87,9%
More Financials
Company
Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic... 
More about the company
Ratings of Synlogic, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about SYNLOGIC, INC.
01:40pTop Midday Gainers
MT
01:36pSYNLOGIC : Piper Sandler Adjusts Synlogic PT to $9 From $7, Maintains Overweight..
MT
09:52aSYNLOGIC : PKU Clinical Program Update
PU
09:15aHealth Care Stocks Trade Lower Pre-Bell Monday
MT
08:05aSYNLOGIC, INC. : Regulation FD Disclosure, Other Events, Financial Statements an..
AQ
07:38aSYNLOGIC : Says Rare Disease Drugs Show Potential Benefit to Patients in Separat..
MT
06:31aSYNLOGIC : Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phe..
PR
09/10SYNLOGIC : Presents at Global PKU Patient Meeting
PR
09/10Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urol..
CI
09/10SAFETY AND TOLERABILITY OF AN OXALAT : SYNB8802 in Healthy Volunteers with Induc..
PU
09/07SYNTHETIC BIOTIC MEDICINES FOR THE T : Global PKU Patient Conference
PU
08/23SYNLOGIC : Development of a Synthetic Biotic, SYNB8802, for the Treatment of Ent..
PU
08/12SYNLOGIC : Reports Second Quarter Financial Results and Provides Business Update..
PU
08/12SYNLOGIC, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
08/12SYNLOGIC : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
More news
News in other languages on SYNLOGIC, INC.

- No features available -

More news
Analyst Recommendations on SYNLOGIC, INC.
More recommendations
Chart SYNLOGIC, INC.
Duration : Period :
Synlogic, Inc. Technical Analysis Chart | SYBX | US87166L1008 | MarketScreener
Technical analysis trends SYNLOGIC, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 3,29 $
Average target price 9,33 $
Spread / Average Target 184%
EPS Revisions
Managers and Directors
Aoife M. Brennan President, Chief Executive Officer & Director
Gregg D. Beloff Chief Financial Officer
Peter Barrett Chairman
David L. Hava Chief Scientific Officer
Antoine Awad Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
SYNLOGIC, INC.52.31%172
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.43.07%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420